ArticleFrontiers in endocrinology2025
Thyroid-stimulating immunoglobulin levels during low-dose antithyroid therapy predict Graves' disease relapse.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Graves' disease (GD) is a common autoimmune disorder often treated with antithyroid drugs (ATD), but relapse rates remain high after therapy withdrawal. This study evaluates the role of thyroid-stimulating immunoglobulin (TSI) levels in predicting relapse after ATD discontinuation in GD patients. Methods: A retrospective analysis of 349 GD patients who achieved euthyroid status on maintenance ATD therapy was conducted. TSI levels were measured using a chemiluminescent immunoassay. Of these, 88 patients discontinued ATD therapy and were monitored for relapse. Statistical analyses, including receiver operating characteristic curve analysis, were used to identify relapse predictors. Results: The median TSI level was significantly higher in patients who relapsed (1.63 vs. 0.52 IU/L, p<0.01), and a cutoff of 1.31 IU/L yielded 63.64% sensitivity, 78.79% specificity, and 86.67% negative predictive value. Independent relapse predictors included a TSI ≥1.31 IU/L, treatment duration of less than 18 months, and the presence of thyroid eye disease. Conclusion: TSI measurement is a valuable tool for predicting relapse after ATD withdrawal in GD. A TSI cutoff of 1.31 IU/L can aid in clinical decision-making, but further prospective studies are required to confirm these findings.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.